| Symbol
| NR4A2
| contributors: mct - updated : 16-01-2015
|
| HGNC name
| nuclear receptor subfamily 4, group A, member 2
|
| HGNC id
| 7981
|
| corresponding disease(s)
|
PARK26
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
| germinal mutation
|
|
|
| |
in familial Parkinson disease | | constitutional
|
|
| --over
|
| |
in cartilage derived from patients with osteoarthritis | | constitutional
|
|
| --over
|
| |
in the T cells isolated from the CNS of multiple sclerosis | | constitutional
|
|
| --low
|
|
in end-stage dilated cardiomyopathy  | | constitutional
|
|
| --low
|
| |
in patients with Parkinson disease | |
| Susceptibility
|
to attention deficit hyperactivity disorder (ADHD) to Parkinson disease to autism spectrum disorder (ASD) |
| Variant & Polymorphism
other
| polymorphisms associated to attention deficit hyperactivity disorder (ADHD) |
|
copy-number variants (CNVs) in NR4A2 contribute significantly to autism spectrum disorder (ASD) risk |
| 
|
Candidate gene
Marker
| Therapy target
| molecular target for blocking inflammation and tissue destruction associated with chronic inflammatory diseases | |
essential transcription factor for triggering the inflammatory cascade of multiple sclerosis and may serve as a therapeutic target | |
| | |
|
| expression increased in diabetic mice that exhibit elevated gluconeogenesis | |
Nurr1 ablation in mice recapitulates early features of Parkinson disease |